The GHK-Cu oral vs injectable debate is, for most serious researchers, not much of a debate at all
Concomitant potassium supplementation in the form of medication, potassium-containing salt substitute or potassium-enriched diets should also not be used
should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus Discontinue treatment in women at least 2 months before a planned pregnancy, owing to the long washout period for semaglutide Clinical Considerations Poorly controlled diabetes during pregnancy increases maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications Poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia-related Interaction Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase the risk of hypoglycemia
Also, any information on retatrutide dosing for weight loss is based on current data, but research is ongoing and FDA approval is pending
